Zyn and the Nicotine Pouch Revolution: The Product Eating the Vape Market

It looks like a mint tin, costs about $5, and slips discreetly between the gum and upper lip. No smoke, no vapor, no smell, no spitting. Within 15 minutes, the nicotine hits the bloodstream through the oral mucosa—smoother than a cigarette, faster than a patch, invisible to everyone around you. This is the nicotine pouch, and it is reshaping the global nicotine market so rapidly that even industry analysts are struggling to keep up. Philip Morris International's Zyn brand alone shipped over 500 million cans in 2024, and the category is growing at rates that make the vaping boom of the 2010s look sluggish. The nicotine pouch isn't just another product category. It may be the product that finally makes smoking obsolete.

The pouch's appeal rests on three pillars that vaping never fully achieved: discretion, simplicity, and regulatory arbitrage. Unlike vapes, which produce visible aerosol and require battery charging, coil replacement, and e-liquid refilling, a nicotine pouch is purely analog—open the can, place a pouch, discard when done. It can be used anywhere: on a plane, in an office meeting, during a movie. For nicotine users who are tired of being exiled to doorways and designated smoking areas, the pouch offers liberation from the social stigma that still clings to visible nicotine use. The simplicity also lowers the barrier to trial; there's no device to buy, no learning curve, no maintenance. It's nicotine stripped to its essence.

The regulatory dimension is equally significant. Nicotine pouches contain no tobacco leaf—only nicotine extract, plant fiber, flavoring, and sweetener—which means they don't fall under tobacco product regulations in many jurisdictions. In the United States, the FDA has authority over them as 'tobacco products' derived from tobacco-derived nicotine, but the regulatory pathway is less onerous than for combustible or vapor products. In Europe, the classification varies by country; pouches are legal consumer products in some nations and effectively banned in others. This patchwork creates both opportunity (markets with no regulatory barriers) and risk (the threat of sudden restriction), and the industry is navigating both aggressively.

The demographic profile of pouch users tells an important story. Unlike vaping, which split its user base between adult ex-smokers and teenagers, pouches have initially skewed heavily toward adult males—particularly former smokers and vapers in their 20s and 30s. The 'Zynfluencer' subculture on TikTok and Instagram, characterized by young men posting videos with pouches tucked into their upper lips, has generated both free marketing and public health concern. In May 2026, the WHO explicitly warned that nicotine pouch brands are targeting youth through social media, citing marketing tactics that echo those used to promote vaping to teenagers. Whether pouches follow vaping's trajectory from adult cessation tool to youth initiation product is the question keeping regulators up at night.

The competitive landscape is intensifying rapidly. PMI's Zyn dominates the US market, but competitors are piling in: British American Tobacco's Velo, Altria's on!, Japan Tobacco International's Nordic Spirit, and a flood of independent brands are fighting for shelf space. The products are differentiated primarily by nicotine strength (ranging from 1.5mg to 15mg+ per pouch), flavor variety (citrus, mint, coffee, cinnamon, and increasingly exotic options), and format (slim, mini, and full-size pouches). Price competition is compressing margins, but the overall category growth has been sufficient to keep all major players investing heavily.

For public health, pouches present the same dilemma as vaping—amplified. On one hand, a product that delivers nicotine without combustion, without tobacco-specific nitrosamines, and without secondhand exposure is clearly preferable to cigarettes on any risk continuum. Swedish snus, the closest analog, has a decades-long epidemiological record showing minimal excess mortality compared to never-tobacco use. On the other hand, pouches are so easy to use and conceal that they could attract never-nicotine users who would have been deterred by the friction of smoking or vaping. A 2024 study in *Nicotine & Tobacco Research* found that 15% of US pouch users had never used any nicotine product before—a proportion that's rising among younger cohorts.

The nicotine pouch revolution is still in its early chapters. If the category follows the trajectory of snus in Sweden—widely adopted by smokers, minimally attractive to never-users, and supported by proportionate regulation—it could be the most significant public health advance since the invention of nicotine replacement therapy. If it follows the trajectory of disposable vapes—aggressively marketed to youth, minimally regulated, and normalized as a lifestyle accessory—it will become the next front in the seemingly endless war over nicotine. The difference between those futures will be determined not by the product itself, but by the regulatory choices made in the next three to five years. As one tobacco control researcher noted: 'Pouches could make cigarettes obsolete. They could also make nicotine addiction universal. The product is neutral. The policy isn't.'